Abzena lays off more than 60 employees in California

26 Jan 2023
endpts.com
VaccineAcquisitionExecutive Change
Contract manufacturer Abzena has permanently laid off 66 employees at one of its San Diego sites, marking the latest in a string of layoffs spanning the biotech industry. The layoffs took effect on Jan. 11 at the company’s 8810 Rehco Road site, according to a WARN notice filed with the Employment Development Department of California. Abzena does have another location in the San Diego area, where the manufacturer invested $60 million and added 50,000 square feet in 2020 . Endpoints News reached out to Abzena but has not received a response as of press time. Just last week, Pfizer announced a deal to scoop up Abzena’s Sanford, NC manufacturing plant for an undisclosed amount. Abzena netted a $65 million investment last year to expand its drug substance and fill-finish manufacturing capacity at the Sanford site, and Pfizer expects the deal to close sometime this quarter. The company also tapped a new CEO, Matthew Stober, at the beginning of the month. Stober previously served as CEO of CastleVax and Istari Oncology and held executive positions at Merck, Novartis and GSK. He was also “instrumental in helping lead the operational turn-around of Hospira,” resulting in its $17 billion sale to Pfizer, according to a news release. The layoffs follow a string of cuts across the industry. Late last year, contract manufacturer Catalent announced that it was axing around 600 positions in Maryland, Texas and Indiana. Catalent’s Bloomington, IN location, which has been a producer of Covid-19 vaccinesCovid-19 vaccines, will have around 400 positions cut. Earlier in January, the Maryland-based manufacturer Emergent said that it will lay off 132 employees as part of its plan to combine its research, product development, and clinical teams into a single “Science & Development” team. The layoffs amount to around 5% of Emergent’s current workforce.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.